(NYSE: ABBV) today authorized a new $5 billion stock repurchase program and increased the company's quarterly cash dividend by nearly 17 percent
Texte intégral
(2)
Documents relatifs
As reported GAAP Adjusted for specified items: Intangible asset amortization Separation costs R&D Acquired IPR&D Calico collaboration Shire transaction costs Other As
The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most
- Reports Second-Quarter Adjusted EPS of $0.82, Above Previous Guidance Range of $0.75 to $0.77 Reports GAAP EPS of $0.68 - Delivers Second-Quarter Revenue of $4.926 Billion,
AbbVie Reports First-Quarter 2014 Financial Results - Reports First-Quarter Adjusted EPS of $0.71, Up 4.4 Percent and Above Previous Guidance Range of $0.67 to $0.69 Reports GAAP EPS
Reports Third-Quarter Adjusted EPS of $0.82, Above Previous Guidance Range; GAAP EPS of $0.60 Raises 2013 Adjusted EPS Guidance to $3.11-$3.13, GAAP EPS Guidance of $2.54-$2.56
The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most
dollars and 8% in local currency to $11.1 billion --- EPS are $1.91, a 10% increase --- Operating income increases 7% to $1.49 billion, with operating margin of 13.4%, an expansion
operations could be materially adversely affected by fluctuations in foreign currency exchange rates; as a result of Accenture’s geographically diverse operations and its